18 FDG-PET/CT for predicting the outcome in ER+/HER2- breast cancer patients: comparison of clinicopathological parameters and PET image-derived indices including tumor texture analysis

摘要: This study investigated the value of some clinicopathological parameters and 18 F-fluorodeoxyglucose-positron emission tomography/computed tomography (18FDG-PET/CT) indices, including textural features, to predict event-free survival (EFS) in estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2-) locally advanced breast cancer (BC) patients. FDG-PET/CT indices were assessed before neoadjuvant chemotherapy (NAC). After completion chemotherapy, all patients had surgery with axillary lymph node dissection, followed by radiation therapy endocrine for 5 years. EFS was estimated using Kaplan-Meier method. A Cox proportional hazard regression model used multivariate analysis. One hundred forty-three consecutive stage II–III ER+/HER2- BC without distant metastases at baseline PET included. High standardized uptake values (SUVs), associated shorter (HR = 3.51, P < 0.01 SUVmax; HR = 2.76, P = 0.02 SUVmean; HR = 4.40 SUVpeak). Metabolically active tumor volume (MATV, HR = 3.47, P < 0.01) total lesion glycolysis (TLG, HR = 3.10, also predictive EFS. Homogeneity not (HR = 2.27, P = 0.07) entropy weak prediction (HR = 2.89, P = 0.02). Among parameters, progesterone (PR)-negative (vs. PR-positive tumor; HR = 3.25, P < 0.01); histology (lobular vs. ductal invasive carcinoma; HR = 3.74, P = 0.01) but grade (grade 3 1–2; HR = 1.64, P = 0.32). Pathological complete response after NAC correlated risk relapse. Three remained significantly MATV (HR = 1.01, P < 0.01), expression (HR = 2.90, P = 0.03) (HR = 3.80, Baseline measured treatment have prognostic analysis, metabolically remains significant while analysis images is added value. Considering histopathological our shows that PR-negative or lobular poorer prognosis than carcinoma, respectively.